论文部分内容阅读
作者对Anderson 医院325例分化型甲状腺癌病人的~(131)I 治疗进行了长期随访分析。在治疗中,乳头状癌、滤泡癌及乳头——滤泡混合癌的生存率并无显著性差异,而Hiirthle 细胞癌生存率明显低。在随访20年中,78%的乳头状癌、68%滤泡癌及70%的乳头——滤泡混合癌仍存活,25年后大约还有65%的病人存活,而Hiirthle 细胞癌16年后病人生存率为40%。在死亡的44例中,19例为混合型乳头——滤泡癌(占该型癌的8%),13例为滤泡癌(22%),7例为乳头状癌(16%),5例为Hi-irthle 细胞癌(38%)。
The authors conducted a long-term follow-up analysis of 131I treatment in 325 patients with differentiated thyroid cancer at Anderson Hospital. In the treatment, there was no significant difference in the survival rate of papillary carcinoma, follicular carcinoma, and nipple-follicular mixed carcinoma, but the survival rate of Hiirthle cell carcinoma was significantly lower. During follow-up of 20 years, 78% of papillary carcinomas, 68% of follicular carcinomas, and 70% of nipple-follicular mixed carcinomas survived, and approximately 65% of patients survived 25 years later, and Hiirthle cell carcinoma has 16 years. After the patient survival rate was 40%. Of the 44 deaths, 19 were mixed nipples-follicular carcinoma (8% of the carcinoma), 13 were follicular carcinoma (22%), and 7 were papillary carcinoma (16%). Five cases were Hi-irthle cell carcinoma (38%).